Hyderabad’s Quantum Leap: How Atomic Cubit and Quantamathical Are Shaping Science’s Next Frontier

From Hyderabad to the Next Realm of Physics

 The Rise of Atomic Cubit and Quantamathical

How Two Young Founders Are Building Quantum Computing and Quantum-Driven Drug Discovery Companies from India

Part-1

Software engineers surprising Experts in Molecule Science

In an era where startup success is often measured by rapid growth, quick funding rounds, and short-term market disruption, two young founders from Hyderabad have chosen a far more difficult path. Instead of building consumer applications, delivery platforms, or financial technology products, they set out to tackle two of the world’s most challenging scientific frontiers- quantum computing and drug discovery.

What began as a vision shared between two determined innovators has evolved into two deep-technology companies with ambitious goals. Today, Atomic Cubit and Quantamathical Private Limited represent a growing belief that world-class scientific innovation can emerge from India and contribute to solving global challenges.

Behind both companies are Naidu Nikhil Bhushan, Chief Executive Officer, and Palle Sai Tilak, Chief Technology Officer. Over the last four years, they have dedicated themselves to understanding, researching, and developing technologies that could influence the future of computation, healthcare, and scientific discovery.

Their story is not one of overnight success. It is a story of persistence, self-belief, continuous learning, and a conviction that Indian innovators can compete in some of the world’s most advanced technological domains.

“We wanted to prove that breakthrough scientific innovation can be built in India,” says Nikhil. “Not someday in the future, but now. We wanted to demonstrate that young Indian founders can contribute to technologies that will define the coming decades.”, Nikhil said.

For Sai Tilak, the motivation was equally clear. “Many people look at quantum computing and advanced scientific research as something that only large corporations or major research institutions can pursue. We wanted to challenge that assumption and build something meaningful ourselves.”

Four Years of Building Against the Odds

The journey began without the advantages often associated with deep-technology ventures. There were no large laboratories, no major institutional grants, and no substantial venture capital backing. Instead, there were long hours of study, research papers, simulations, technical discussions, and countless experiments. The founders spent years immersing themselves in emerging scientific literature, understanding quantum computing architectures, exploring computational chemistry, and identifying areas where meaningful contributions could be made.

Unlike many startups that can validate ideas within months, deep-tech companies often require years before visible milestones emerge. Progress is measured not by downloads or monthly active users, but by research achievements, technical breakthroughs, architectural innovations, and scientific understanding.

“There were moments when the journey felt overwhelming,” recalls Nikhil. “Deep-tech entrepreneurship requires patience because the timelines are different. You may spend years building foundations before anyone outside your team sees the outcome.” What kept them moving forward was a combination of determination and support from their families.

“Our parents believed in us from the beginning. That support gave us confidence to continue working toward goals that many people considered too ambitious. That belief ultimately became the foundation upon which two companies were built. says Sai Tilak. “Our parents believed in us from the beginning,” says Sai Tilak. “That support gave us confidence to continue working toward goals that many people considered too ambitious. That belief ultimately became the foundation upon which two companies were built”. Sai Tilak said.

Atomic Cubit: Designing the Future of Computation

Quantum computing is widely regarded as one of the most transformative technologies currently under development. While classical computers process information using bits that represent either 0 or 1, quantum computers use quantum bits, or qubits, which can exist in multiple states simultaneously through quantum mechanical phenomena. This capability creates entirely new computational possibilities and has the potential to address problems that remain extremely difficult for conventional computing systems. Governments and technology companies around the world have invested billions of dollars into quantum research because of its potential applications in optimization, materials science, cryptography, artificial intelligence, logistics, climate modeling, and pharmaceutical development.

Recognizing both the opportunity and the challenge, the founders established Atomic Cubit with a mission to contribute to India’s participation in the global quantum ecosystem. Rather than focusing solely on software applications, Atomic Cubit chose one of the most technically demanding areas of quantum technology: processor architecture and hardware design. Over several years, the company conducted extensive work on processor connectivity, quantum error correction, signal routing, scalability challenges, and architecture optimization. These engineering challenges are among the most significant barriers preventing large-scale quantum computing from becoming a reality.

The culmination of this work has been the completion of the design of Nandi Q1, Atomic Cubit’s first four-qubit entangled quantum processor. For the founders, the significance of Nandi Q1 extends beyond the number of qubits involved. The achievement represents the successful translation of years of research into a tangible processor architecture.

“Many people focus exclusively on qubit counts,” explains Sai Tilak. “But building a useful quantum computer is not simply about adding more qubits. Architecture, connectivity, routing efficiency, error correction, and scalability are equally important.”, Nikhil said.

Atomic Cubit: Building Scalable, Error-Corrected Quantum Processors

Nandi Q1 was developed with these considerations in mind. The processor serves as a foundational platform for future generations of Atomic Cubit’s quantum technologies and reflects the company’s long-term emphasis on scalable engineering principles. The team’s research has also focused heavily on what they describe as an error-correction-first approach to architecture development. As quantum systems scale, errors become increasingly difficult to manage. Without effective error correction, larger quantum systems cannot reliably perform useful computations.

By addressing these challenges early in the design process, Atomic Cubit aims to contribute architectural innovations that support future scalability. For a young Indian startup operating with limited resources, completing a quantum processor design represents a significant technical milestone and a demonstration of indigenous capability.

Beyond Hardware: Building a Quantum Ecosystem

The founders believe that India’s opportunity in quantum computing extends beyond individual technologies. They envision an ecosystem where universities, startups, government initiatives, researchers, and private industry collaborate to accelerate scientific advancement. India’s National Quantum Mission has already highlighted the strategic importance of quantum technologies, while state-level initiatives such as Andhra Pradesh’s emerging Quantum Valley vision seek to create supportive environments for research and commercialization.

According to the founders, startups will play a critical role in translating scientific research into practical technologies. “Quantum computing is not just a scientific challenge,” says Nikhil. “It is also an economic opportunity. The countries that build expertise today will shape industries tomorrow.” Atomic Cubit aims to be part of that transformation.

Quantamathical: Reimagining Drug Discovery

While Atomic Cubit focuses on the future of computation, Quantamathical focuses on one of humanity’s most important challenges: improving healthcare outcomes through faster and more efficient drug discovery. The pharmaceutical industry faces enormous complexity. Developing a single new medicine can require years of research, extensive experimentation, multiple rounds of optimization, and substantial financial investment. Researchers often evaluate thousands of molecular candidates before identifying a handful worthy of further development. This process contributes significantly to the cost and timeline associated with bringing new therapies to patients. Quantamathical was founded with the belief that advanced computational methods can help transform this process.

By integrating artificial intelligence, computational chemistry, and quantum-inspired scientific approaches, the company seeks to accelerate the identification and evaluation of promising molecular candidates.

Rather than relying solely on traditional trial-and-error methods, computational techniques can help researchers predict molecular interactions, estimate behavior, and prioritize candidates more efficiently.

“Our goal is to reduce the time between scientific discovery and real-world impact,” says Nikhil and he added that if researchers can identify promising molecules earlier and with greater confidence, the entire development process becomes more efficient.”

From Lab to Lifesaving: Accelerating Drug Discovery with Quantum Chemistry

The company has already demonstrated its commitment to scientific research through the publication of a research paper focused on near-term quantum chemistry applications. The publication explores how emerging quantum technologies could contribute to molecular simulation and pharmaceutical research in the coming years. For the founders, publishing research is an important component of building credibility. Scientific progress depends upon knowledge sharing, peer review, and collaboration. “We want to contribute to the scientific community, not just build products,” says Sai Tilak.

The company ultimately envisions a future in which advanced computational platforms help pharmaceutical companies, biotechnology firms, and research institutions discover new therapeutic candidates faster and more effectively. Particular attention is being given to diseases where current discovery approaches remain expensive, slow, or technically challenging.

Two-Companies, One Long-Term Vision in Part-2